A team from the University of Queensland reported development of a single‑chain fragment variable (scFv) targeting the membrane‑proximal region of ROR1, demonstrating preclinical activity against triple‑negative breast cancer (TNBC). The design aims to reduce cross‑reactivity with normal tissues by avoiding the Ig‑like domain, and in vitro and in vivo assays showed tumor binding and antitumor effects. The study outlines a next step toward therapeutic candidates for hard‑to‑treat TNBC.